The biopharmaceutical industry stands at a critical juncture where the integration of artificial intelligence (AI) into contract development and manufacturing organizations (CDMOs) is no longer a distant vision but a pressing reality. With the global biopharma market facing mounting pressure to
In the high-stakes world of biopharmaceuticals, where developing a single drug can cost upwards of $2.7 billion, inefficiencies in clinical bioanalysis pose a significant threat to timelines and budgets, often delaying critical decisions by weeks or even months. Traditional manual methods,
In the rapidly advancing realm of synthetic biology, a remarkable innovation is capturing the attention of scientists and industry leaders alike: the potential to produce proteins outside the confines of living cells using synthetic transfer RNA (tRNA) arrays. This cutting-edge development,
In the rapidly evolving field of synthetic biology, a groundbreaking study from the University of Warwick has unveiled a transformative approach to enhance the productivity of engineered microbial cell factories, as detailed in a recent publication in Nature Communications . These microscopic
In a groundbreaking move that has captured the attention of both the pharmaceutical industry and economic analysts, Eli Lilly and Co. has unveiled plans for a staggering $5 billion biomanufacturing facility in Goochland County, Virginia. Nestled in the West Creek Business Park, just a short
The pharmaceutical industry stands at a critical juncture, where the urgent need for faster, more sustainable, and patient-focused solutions is driving unprecedented change, as vividly demonstrated at the DCAT Summit held on June 4–5 in Lugano, Switzerland. Under the compelling theme "Expedition
